{"page":{"totalFilteredElements":343},"studies":[{"active":true,"description":"SURVIVE (Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer) - a partially double-blinded, multicenter, randomized, controlled superiority study<div><br /></div><div>DRKS00030745<br /></div>","eudractNumber":null,"id":9451,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":"NCT05658172","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-03-25T09:29:48+01:00","shortTitle":"SURVIVE","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Screening Programm auf hypermutierte Tumore mit potentiell h&#246;herer Immunogenit&#228;t und Response auf Immun-Checkpoint-Inhibitoren (PD-1 Blockade)","eudractNumber":null,"id":3702,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"}],"mutations":[{"name":"MSI (Mikrosatelitteninstabilität)","id":"mt_51"}],"nctNumber":null,"phase":null,"recruitmentStart":"2017-05-03T09:47:23+02:00","shortTitle":"Screen-Hyper","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prospective, international, multicenter non-AMG/MPG study to detect possible markers for prediction of seroma development and risk assessment of a breast seroma after mastectomy with or without implant-based breast reconstruction","eudractNumber":null,"id":10643,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":"NCT05899387","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2025-03-10T13:38:44+01:00","shortTitle":"SerMa","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<div>Etablierung einer objektiven digitalen Sprachqualit&#228;tstestung f&#252;r Patienten</div><div>nach Stimmrehabilitation nach totaler Kehlkopfentfernung</div>","eudractNumber":null,"id":9722,"indications":[{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2022-06-01T08:43:32+02:00","shortTitle":"Sprachverständlichkeit nach Laryngektomie","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Studien-, Dokumentations- und Qualit&#228;tszentrum der Deutschen Gesellschaft f&#252;r Allgemein- und Viszeralchirurgie","eudractNumber":null,"id":7997,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"sch","name":"Schilddrüsenkarzinom"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2012-01-01T09:16:52+01:00","shortTitle":"StuDoQ_Kolon_Pankreas_Schilddrüse","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<div>Register und Biomaterialdatenbank f&#252;r reifzellige systemische T-Zell Lymphome (T-NHL) der German Lymphoma Alliance (GLA) und der Ostdeutschen Studiengruppe H&#228;matologie und Onkologie (OSHO)</div><div><br /></div><div>DRKS00030561</div>","eudractNumber":null,"id":8286,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-07-14T13:56:45+02:00","shortTitle":"T-NHL Register (OSHO & GLA)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<div>A Phase 3, open-label, single-arm, repeated-dose study to evaluate the safety and tolerability, pharmacokinetics, and antiviral activity of maribavir for the treatment of cytomegalovirus (CMV) infection in children and adolescents who have received a hematopoietic stem cell transplant (HSCT) or a solid organ transplant (SOT)</div>","eudractNumber":"2021-004279-15","id":8243,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":"NCT05319353","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-01-09T10:59:40+01:00","shortTitle":"TAK-620-2004 Maribavir","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Entschl&#252;sselung der gest&#246;rten Signalwege des Knochenmarkmikromilieus und des Zusammenspiels zwischen h&#228;matopoetischen und stromalen Zellen bei Myelodysplastischem Syndrom (MDS) und Akuter Myeloischer Leuk&#228;mie (AML)","eudractNumber":null,"id":9066,"indications":[{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2023-06-01T12:53:12+02:00","shortTitle":"TET2","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<div>A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination with Checkpoint Inhibition for the Treatment of Participants with Relapsed or Refractory Multiple Myeloma</div><div><br /></div>","eudractNumber":"2022-502681-24-00","id":7759,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05338775","phase":{"id":"ph_6","name":"Phase IB"},"recruitmentStart":"2022-07-06T15:14:55+02:00","shortTitle":"TRIMM-3, 64407564MMY1005","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"nNGM Task Force 5 Genetic Tumor Risk","eudractNumber":null,"id":8781,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2023-10-16T09:43:41+02:00","shortTitle":"Task Force 5 (nNGM)","therapeutical":false,"therapyLines":[]}]}